Invivyd, Inc. — Form 8-K Summary
Reporting date: September 29, 2026. This current report covers an event announced on that date; it does not report a financial quarter or year.
Business context and event
Invivyd announced positive topline results from its LIBERTY Phase 3 study of VYD2311 and plans for regulatory submissions. The press release title states that VYD2311’s safety and tolerability were superior to those of an mRNA-based COVID-19 vaccine. The 8-K incorporates the press release and an updated corporate presentation as Exhibits 99.1 and 99.2, but their contents are not included in the supplied filing text.
Financial and operating metrics
The filing text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Guidance, risks, and unusual items
The company announced regulatory submission plans for VYD2311, but the filing text does not specify timing or provide further detail. It contains no financial guidance or discussion of risks, contingencies, or other unusual items beyond the announcement.
Investor verification points
- Review Exhibit 99.1 for the full LIBERTY trial results, including study design, endpoints, participant numbers, statistical details, and safety findings.
- Review Exhibit 99.1 and the updated corporate presentation, Exhibit 99.2, for the scope and timing of planned regulatory submissions.
- Check subsequent company disclosures for regulatory developments and additional clinical data.